Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Hidradenitis Suppurativa in People with Down Syndrome: Screening, Phenotype, and Treatment
Description
The talk focused on hidradenitis suppurativa (HS) in people with Down syndrome, emphasizing that HS is substantially more common in this population, with studies showing adults with Down syndrome are about five times more likely to have HS and adolescent clinic data suggesting high rates of HS and folliculitis. The speaker described a somewhat different phenotype in Down syndrome, often starting as folliculitis on the buttocks and thighs and progressing to inflammatory nodules, pustules, groin, inner thigh, inframammary, neck, and sometimes axillary involvement, with more tunneling in some female patients. Because of this burden, annual screening for HS was recommended beginning around ages 8 to 10. The talk also highlighted quality-of-life and mental health impacts, including depression risk and large effects on patient and caregiver DLQI scores, and stressed the importance of hearing the patient’s voice, communication preferences, and direct engagement in care. Proposed mechanisms included immune dysregulation and interferon pathway overactivity linked to chromosome 21, along with possible roles for amyloid precursor protein in follicular disease. Treatment recommendations favored practical, patient-centered approaches: flexible bathing routines; benzoyl peroxide or bleach baths; clindamycin lotion, metronidazole lotion, erythromycin pads, resorcinol, retinoids, and emerging topical JAK inhibitors; procedural options such as intralesional steroids and laser hair removal; cautious use of zinc, spironolactone, and combined oral contraceptives; selective use of isotretinoin; and careful consideration before oral antibiotics due to prior exposure and resistance concerns. The speaker discussed biologics, especially TNF-alpha inhibitors, but noted concerns about infections, malignancy, cardiac disease, and uncertain efficacy, while suggesting IL-17 agents may have a better safety profile and encouraging screening for inflammatory bowel disease. Finally, the talk noted promising early data on systemic JAK inhibitors and shared resources such as Down syndrome-specific skincare handouts and a monthly HS support group.
View moreConclusions
- Hidradenitis suppurativa appears to be substantially more common in people with Down syndrome than in the general population, so routine annual screening starting in childhood is warranted.
- The HS phenotype in Down syndrome may present somewhat differently, often with folliculitis-like lesions and prominent involvement of the buttocks, thighs, groin, neck, and sometimes axillae.
- HS and other skin disease can meaningfully worsen quality of life for both patients with Down syndrome and their caregivers, so the burden should be taken seriously even when disease seems limited.
- Care for this population should be highly patient-centered and communication-accessible, with clinicians speaking directly to the patient and adapting to sensory and communication needs.
- Basic hygiene and topical regimens should be individualized and flexible, since bathing tolerance and sensory issues can strongly affect adherence and outcomes.
- Topical therapies such as clindamycin, benzoyl peroxide, resorcinol, retinoids, and sometimes metronidazole or erythromycin pads may be useful, especially for milder or more follicular disease.
- Oral antibiotics are often better used sparingly or as rescue therapy because many people with Down syndrome have already had substantial antibiotic exposure.
- Systemic options like spironolactone, isotretinoin, and combined oral contraceptives can help selected patients, but they require cautious dosing and attention to comorbid cardiac, blood pressure, and thrombotic risks.
- Biologics, especially TNF-alpha inhibitors, may help some patients but raise special safety and efficacy questions in Down syndrome, including infection, malignancy, and paradoxical flare concerns.
- IL-17 inhibitors and JAK inhibitors are promising alternatives, but the field still needs more evidence to determine which immune pathways and treatments are most effective in this interferon-driven population.
- Down syndrome-specific education materials and support groups are important adjuncts to medical treatment and can improve family engagement and shared decision-making.
- Dermatol Pract Concept. 2019 Dec; 10(1)
- Pediatr Dermatol. 2024; 41:1047-1052.
- Dermatol Pract Concept. 2019 Dec; 10(1):e2020026
- Br J Plast Surg. 2003 Jul; 56(5): 451-61.
- J Am Acad Dermatol. 2021 Jan 23:S0190-9622(21)00213-9.
- Br J Dermatol. 2023; 189(2): 221-222.
- Genes (Basel). 2021 Feb 13;12(2):268.
- Immunol Cell Biol. 2012;90(5):483-491
- Elife. 2016;5:e16220.